These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 26939853)

  • 1. The Intersection of TNF, IBD and the Microbiome.
    Jones-Hall YL; Nakatsu CH
    Gut Microbes; 2016; 7(1):58-62. PubMed ID: 26939853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allergic and Immunologic Perspectives of Inflammatory Bowel Disease.
    Clarke K; Chintanaboina J
    Clin Rev Allergy Immunol; 2019 Oct; 57(2):179-193. PubMed ID: 29754190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fc Receptor-mediated Effector Function Contributes to the Therapeutic Response of Anti-TNF Monoclonal Antibodies in a Mouse Model of Inflammatory Bowel Disease.
    McRae BL; Levin AD; Wildenberg ME; Koelink PJ; Bousquet P; Mikaelian I; Sterman AS; Bryant S; D'Haens G; Kamath R; Salfeld J; van den Brink GR
    J Crohns Colitis; 2016 Jan; 10(1):69-76. PubMed ID: 26429698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
    J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enterocyte dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin expression in inflammatory bowel disease.
    Zeng JQ; Xu CD; Zhou T; Wu J; Lin K; Liu W; Wang XQ
    World J Gastroenterol; 2015 Jan; 21(1):187-95. PubMed ID: 25574091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease.
    Van den Brande JM; Koehler TC; Zelinkova Z; Bennink RJ; te Velde AA; ten Cate FJ; van Deventer SJ; Peppelenbosch MP; Hommes DW
    Gut; 2007 Apr; 56(4):509-17. PubMed ID: 17082252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.
    Fréling E; Baumann C; Cuny JF; Bigard MA; Schmutz JL; Barbaud A; Peyrin-Biroulet L
    Am J Gastroenterol; 2015 Aug; 110(8):1186-96. PubMed ID: 26195181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
    Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Romanko I; Bina V; Malickova K; Kolar M; Lukas M
    Scand J Gastroenterol; 2016; 51(2):196-202. PubMed ID: 26329773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents.
    Karmiris K; Bossuyt P; Sorrentino D; Moreels T; Scarcelli A; Legido J; Dotan I; Naismith GD; Jussila A; Preiss JC; Kruis W; Li AC; Bouguen G; Yanai H; Steinwurz F; Katsanos KH; Subramaniam K; Tarabar D; Zaganas IV; Ben-Horin S;
    J Crohns Colitis; 2015 May; 9(5):382-9. PubMed ID: 25740813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Damage-associated molecular patterns in inflammatory bowel disease: From biomarkers to therapeutic targets.
    Nanini HF; Bernardazzi C; Castro F; de Souza HSP
    World J Gastroenterol; 2018 Nov; 24(41):4622-4634. PubMed ID: 30416310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4+ immune response as a potential biomarker of patient reported inflammatory bowel disease (IBD) activity.
    Brandhorst G; Weigand S; Eberle C; Raddatz D; Karaus M; Oellerich M; Walson PD
    Clin Chim Acta; 2013 Jun; 421():31-3. PubMed ID: 23485644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update.
    Denmark VK; Mayer L
    Expert Rev Clin Immunol; 2013 Jan; 9(1):77-92. PubMed ID: 23256766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solid Organ Transplantation in Patients with Inflammatory Bowel Diseases (IBD): Analysis of Transplantation Outcome and IBD Activity in a Large Single Center Cohort.
    Schnitzler F; Friedrich M; Stallhofer J; Schönermarck U; Fischereder M; Habicht A; Karbalai N; Wolf C; Angelberger M; Olszak T; Beigel F; Tillack C; Göke B; Zachoval R; Denk G; Guba M; Rust C; Grüner N; Brand S
    PLoS One; 2015; 10(8):e0135807. PubMed ID: 26288187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the fecal, cecal, and mucus microbiome in male and female mice after TNBS-induced colitis.
    Kozik AJ; Nakatsu CH; Chun H; Jones-Hall YL
    PLoS One; 2019; 14(11):e0225079. PubMed ID: 31703107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complications and surgery in the inflammatory bowel diseases biological era.
    Sokol H; Seksik P; Cosnes J
    Curr Opin Gastroenterol; 2014 Jul; 30(4):378-84. PubMed ID: 24840000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolate Mofetil Modulates Differentiation of Th1/Th2 and the Secretion of Cytokines in an Active Crohn's Disease Mouse Model.
    Lv QK; Liu JX; Li SN; Gao YJ; Lv Y; Xu ZP; Huang BX; Xu SY; Yang DX; Zeng YL; Liu DF; Wang W
    Int J Mol Sci; 2015 Nov; 16(11):26654-66. PubMed ID: 26561804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An antibiotic-responsive mouse model of fulminant ulcerative colitis.
    Kang SS; Bloom SM; Norian LA; Geske MJ; Flavell RA; Stappenbeck TS; Allen PM
    PLoS Med; 2008 Mar; 5(3):e41. PubMed ID: 18318596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel agents in the future: Therapy beyond anti-TNF agents in inflammatory bowel disease.
    Peng JC; Shen J; Ran ZH
    J Dig Dis; 2014 Nov; 15(11):585-90. PubMed ID: 25251263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Necrosis Factor and Lymphotoxin in Regulation of Intestinal Inflammation.
    Gubernatorova EO; Tumanov AV
    Biochemistry (Mosc); 2016 Nov; 81(11):1309-1325. PubMed ID: 27914457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.